{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:13:19Z","timestamp":1771661599364,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Mannitol is exclusively recommended in the National Comprehensive Cancer Network guidelines for diuresis in cisplatin (CDDP)\u2010based chemotherapy. The utility of furosemide, a widely used and convenient diuretic, thus requires clarification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a prospective, single\u2010centered, open\u2010label, noninferiority phase II study. Patients with thoracic malignancies who planned to receive CDDP\u2010based chemotherapy were randomly assigned to receive either mannitol (arm A) or furosemide (arm B). The primary end point was set as the proportion of patients who experienced any grade of \u201ccreatinine (Cr) increased\u201d based on the upper limit of the normal range (ULN) during the first cycle as assessed by Common Terminology Criteria for Adverse Events Version 4.0. Secondary end points were Cr increased based on the baseline value during the first cycle, Cr increased after the completion of CDDP, and the proportion of patients with phlebitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between April 2018 and March 2022, 115 patients were enrolled and 106 were analyzed. Any grade of Cr increased based on the ULN during the first cycle was 17.3% (arm A) and 24.1% (arm B), respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.34). Therefore, the primary end point was not met. After completion of chemotherapy, any grade of Cr increased was observed in 23.1% (arm A) and 31.5% (arm B), respectively. However, the actual serum Cr level and Cr clearance during the courses were not different between the arms. Phlebitis occurred more frequently in arm A (28.8%) than arm B (16.7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Mannitol should remain the standard diuresis in CDDP\u2010based chemotherapy assessed by conventional CTCAE grading, but furosemide can be room for consideration when assessed by actual serum Cr level and Cr clearance.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6839","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T15:59:55Z","timestamp":1709913595000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin\u2010based chemotherapy using short hydration: A randomized phase <scp>II<\/scp> trial"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9062-8250","authenticated-orcid":false,"given":"Eriko","family":"Murakami","sequence":"first","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5856-5512","authenticated-orcid":false,"given":"Hiroaki","family":"Akamatsu","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Teraoka","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Takakura","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Takase","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kaki","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Harutani","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Furuta","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeya","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Shibaki","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daichi","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hayata","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3798-3488","authenticated-orcid":false,"given":"Yuichi","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8758-8980","authenticated-orcid":false,"given":"Yasuhiro","family":"Koh","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"},{"name":"Center for Biomedical Sciences Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Clinical Study Support Center Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Internal Medicine III Wakayama Medical University  Wakayama Japan"},{"name":"Center for Biomedical Sciences Wakayama Medical University  Wakayama Japan"},{"name":"Clinical Study Support Center Wakayama Medical University  Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02098-5"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01764.x"},{"key":"e_1_2_10_5_1","first-page":"551","article-title":"Mechanism of cis\u2010platinum nephrotoxicity: II. Morphologic observations","volume":"213","author":"Dobyan DC","year":"1980","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197704)39:4<1357::AID-CNCR2820390402>3.0.CO;2-C"},{"issue":"4","key":"e_1_2_10_7_1","first-page":"1269","article-title":"Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis\u2010dichlorodiammineplatinum\u2010(II) in rats","volume":"39","author":"Pera MF","year":"1979","journal-title":"Cancer Res"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q333"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014533303"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2978-0"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05703-7"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00275"},{"key":"e_1_2_10_13_1","unstructured":"National Comprehensive Cancer Network Chemotherapy Order Templates. Accessed April 21 2023.https:\/\/www.nccn.org\/compendia\u2010templates\/nccn\u2010templates\u2010main\/browse\u2010by\u2010cancer\u2010type"},{"issue":"6","key":"e_1_2_10_14_1","first-page":"730","article-title":"Retrospective analysis of short\u2010hydration cisplatin\u2010based chemotherapy","volume":"2","author":"Korogi Y","year":"2013","journal-title":"Ann Jpn Respir Soc"},{"issue":"1","key":"e_1_2_10_15_1","first-page":"73","article-title":"High\u2010dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity","volume":"65","author":"Ostrow S","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0620-1"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13423"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2983195"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4789"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029057"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt122"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt128"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12509"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T05:02:40Z","timestamp":1710219760000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1002\/cam4.6839"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6839","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2023-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e6839"}}